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Background: We and others have recently shown that tumor characteristics are altered throughout tumor progression.
These findings emphasize the need for re-examination of tumor characteristics at relapse and have led to recommenda-
tions from ESMO and the Swedish Breast Cancer group. Here, we aim to determine whether tumor characteristics and
molecular subtypes in breast cancer metastases confer clinically relevant prognostic information for patients.
Patients and methods: The translational aspect of the Swedish multicenter randomized trial called TEX included
111 patients with at least one biopsy from a morphologically confirmed locoregional or distant breast cancer metastasis
diagnosed from December 2002 until June 2007. All patients had detailed clinical information, complete follow-up,
and metastasis gene expression information (Affymetrix array GPL10379). We assessed the previously published
gene expression modules describing biological processes [proliferation, apoptosis, human epidermal receptor 2
(HER2) and estrogen (ER) signaling, tumor invasion, immune response, and angiogenesis] and pathways (Ras, MAPK,
PTEN, AKT-MTOR, PI3KCA, IGF1, Src, Myc, E2F3, and β-catenin) and the intrinsic subtypes (PAM50). Furthermore,
by contrasting genes expressed in the metastases in relation to survival, we derived a poor metastasis survival
signature.
Results: A significant reduction in post-relapse breast cancer-specific survival was associated with low-ER receptor
signaling and apoptosis gene module scores, and high AKT-MTOR, Ras, and β-catenin module scores. Similarly, intrin-
sic subtyping of the metastases provided statistically significant post-relapse survival information with the worst survival
outcome in the basal-like [hazard ratio (HR) 3.7; 95% confidence interval (CI) 1.3–10.9] and HER2-enriched (HR 4.4;
95% CI 1.5–12.8) subtypes compared with the luminal A subtype. Overall, 25% of the metastases were basal-like,
32% HER2-enriched, 10% luminal A, 28% luminal B, and 5% normal-like.
Conclusions: We show that tumor characteristics and molecular subtypes of breast cancer metastases significantly
influence post-relapse patient survival, emphasizing that molecular investigations at relapse provide prognostic and
clinically relevant information.
ClinicalTrials.gov: This is the translational part of the Swedish multicenter and randomized trial TEX, clinicaltrials.gov
identifier nct01433614 (http://www.clinicaltrials.gov/ct2/show/nct01433614).
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introduction
Breast cancer is widely recognized as a heterogeneous disease in
the sense of both primary tumor metastatic capacity and time to
metastatic spread of disease. Treatment with endocrine therapy
is a major cornerstone in the management of breast cancer and
has considerably improved patient survival. However, despite
considerable progress, one of five women with early-stage breast
cancer will later develop distant metastatic disease [1].
We and others have recently shown that tumor characteristics
are altered throughout tumor progression [2–4], which signifi-
cantly influences patient survival [2, 5]. These findings empha-
size the need for re-examination of tumor characteristics at relapse
to improve patient management and have led to recommenda-
tions from the ABC1, ASCO, ESMO, and Swedish Breast Cancer
group (SweBCG), among others, regarding the re-evaluation of
metastatic lesions for expression of estrogen (ER), progesterone
(PR), and human epidermal receptor 2 (HER2) [6–8].
Here, we aimed to enhance our understanding of the biology
of breast cancer metastases in relation to post-relapse survival
and to assess tumor characteristics with previously demon-
strated prognostic significance in the primary tumor setting to
understand their importance in metastatic disease. Our goal in
doing so is to provide biologically relevant information that will
help to guide individualized patient management. We analyzed
tumor characteristics from one or more metastases of 111 breast
cancer patients enrolled in the Swedish multicenter prospective
and randomized TEX [Taxol® (paclitaxel): Bristol-Myers Squibb
AB, Sweden; Farmorubicin® (epirubicin): Pfizer AB, Sweden;
Xeloda® (capecitabine): Roche AB, Sweden] trial.
patients andmethods
The Swedish multicenter and randomized trial TEX [9], ClinicalTrials.gov
identifier NCT01433614 (http://www.clinicaltrials.gov/ct2/show/NCT01433614),
enrolled 287 patients with a morphologically confirmed locoregional or
distant breast cancer relapse from December 2002 until June 2007. Previous
endocrine treatment of advanced disease in patients with hormone receptor-
positive breast cancer was allowed. In addition, previous treatment with an
anthracycline, a taxane, or 5-FU was allowed if the last course of chemother-
apy was given at least 1 year before TEX study entry. Patients were randomly
assigned to first-line chemotherapy with a combination of epirubicin and
paclitaxel alone or in combination with capecitabine. Detailed clinical infor-
mation and complete follow-up were available for all included patients.
Patients with metastatic lesions accessible for either a fine-needle aspir-
ation (FNA) or a core biopsy were asked to give a sample, but sampling was
optional. We defined the site of relapse as the site where the metastatic
biopsy was taken. The most common biopsy sites were lymph nodes
(36.7%), liver (22.5%), skin (18.3%), and breast (15.8%). In total, tumor
tissue was available from 149 of 287 patients.
The translational aspect of the trial included 120 relapse biopsies (116
FNA biopsies and 4 core biopsies) from 111 patients yielding sufficient
tumor RNA for gene expression profiling. The clinical and pathological
patient characteristics of the translational TEX trial were representative of
the original TEX trial.
Details of the HRSTA-2.0 custom human Affymetrix array GPL10379 are
available at NCBI GEO depository as GPL10379 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GPL10379). Briefly, this whole-genome array
contains 52 378 individual probe sets, with each probe set containing 4–20
individual probes. The gene expression microarray data have been deposited
into the Gene Expression Omnibus under the accession number of GSE56493.
This study was approved by the Ethics committee at Karolinska Institutet
and the other participating centers. All patients have given written informed
consent.
statistical methods
preprocessing and normalization. The relapse tumor gene expression
analyses were performed in the open-source software R using the aroma.
affymetrix package [10]. Each gene expression array was individually
background corrected and normalized using robust multichip averaging;
no arrays were identified as having poor quality. The quality of the arrays
was assessed utilizing Normalized Unscaled Standard Error plots and
Relative Log Expression plots.
survival analysis. Patient follow-up started at the date of the TEX study
enrollment and ended at the date of death, or at the end of study follow-up,
1 July 2013. We carried out Kaplan–Meier and multivariate proportional
hazard (Cox) analyses adjusting for calendar year and age at diagnosis in
addition to the TEX clinical study treatment arms. We did not adjust for
additional tumor characteristics due to sample size. The proportional hazard
assumption for the main exposure variables was assessed including a time-
dependent covariate in the survival model. No significant deviation was
noted.
Breast cancer-specific survival was used as the end point. Post-relapse
patient survival was defined as short-term (up to 1.5 years post-relapse sur-
vival) and long-term survival (up to 5 years or more). The short-term sur-
vival cutoff (1.5 years post-relapse survival) was defined retrospectively by
applying a model of two normal distributions, in order to capture the visual-
ly apparent survival distribution, using the mixtools package in R [11]. A full
description of this is provided in supplementary Materials and methods,
available at Annals of Oncology online.
intrinsic subtype. We assessed the intrinsic subtypes (PAM50) for each
relapse using the TEX metastasis gene expression arrays as previously
described; full details are provided in supplementary Materials and methods,
available at Annals of Oncology online [12].
gene modules. To characterize the tumor biology of the breast cancer
relapses, we applied the set of 7 gene expression process modules and 10
pathway modules as previously described [13, 14]. Each module is
comprised of genes both positively and negatively associated with the gene
of interest (e.g. ESR1) and the module as a whole is representative of a
biological process/pathway. We computed the module score for every gene
module in the relapses and divided the resulting continuous variables into
tertiles as described in the original publications. The tertiles were grouped so
that the most clinically aggressive tertile was compared with the remaining
two.
Hierarchical clustering was used to indicate relapse sample similarity with
respect to post-relapse survival (short- or long-term, see definition above)
and relapse site.
single probe association. Differential gene expression according to short-
or long-term post-relapse patient survival (as defined above) was analyzed using
the open-source R package OCplus 1.22.0 [15]. For additional information, see
supplementary Methods, available at Annals of Oncology online.
All data preparation and analysis were done using SAS version 9.3 and
R version 2.15.2.
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results
The clinico-pathological characteristics of the 111 patients in-
cluded in the translational TEX trial are summarized in Table 1.
The majority of patients were diagnosed with primary breast
cancer from 1995 onwards and as expected from a clinically
aggressive cohort, there were high numbers of ER negative
(37.5%), PR negative (51.5%), grade 3 (52.4%), and stage IV
(14.8%) tumors at primary tumor diagnosis. Metastatic sites
were distributed as follows: breast (15.8%), liver (22.5%),
lung/pleura (1.7%), lymph node (36.7%), skeleton (4.2%), skin
(18.3%), and other 0.8%.
gene expression modules of biological processes
reflect the aggressive nature of breast cancer
metastases
To characterize the tumor biology of breast cancer metastases,
we assessed a set of seven biologically relevant gene expression
modules in our 120 metastatic samples [13]. For visualization
purposes, we selected those genes positively correlated with each
module from our samples and carried out hierarchical clustering
(Figure 1A and B). All gene modules (AURKA—proliferation,
CASP3—apoptosis, ERBB2—HER2 signaling, ESR1—ER sig-
naling, PLAU—tumor invasion/metastasis, STAT1—immune
response, and VEGF—angiogenesis) show a varying range of
expression values emphasizing the biological diversity between
metastases. The aggressive nature of these tumors is also readily
apparent with the majority displaying high expression of genes
related to proliferation (AURKA module) and approximately
half exhibiting low ESR1-related expression (ESR1 module). The
seven patients in our cohort with multiple gene expression arrays
(either several biopsies on the same metastatic site or different
sites) are indicted with colored arrows and numbers (Figure 1A,
bottom of the heatmap). The paired metastases from four of
seven patients cluster immediately beside one another (numbers
1, 4, 5, and 7). Conversely, three metastatic biopsy pairs from the
same patient and relapse cluster separately (numbers 2, 3, and 6),
indicating gene expression pattern differences between these intrar-
elapse tumor biopsies.
low ESR1 and CASP3 gene module scores are
associated with poor post-relapse survival
Long- and short-term Kaplan–Meier survival curves for the
ESR1 and CASP3 gene modules are shown in Figure 2 A and B,
(left panels, and for the remaining modules in supplementary
Figures S1 and S2, available at Annals of Oncology online. Patients
with a low CASP3 module score demonstrated poor long-term sur-
vival relative to those with an intermediate/high score (Figure 2B,
left panel, P = 0.0010). In addition, low ESR1 and CASP3 module
scores were associated with poor short-term breast cancer-specific
survival (Figure 2A and B, right panels, P = 0.0078 and P = 0.045,
respectively). Furthermore, using a multivariate proportional
hazard (Cox) model adjusting for age at diagnosis, diagnosis
date, and TEX clinical study treatment received, a more than
twofold increased risk for death from breast cancer (short-term
survival) was found in patients whose tumors had low CASP3
and ESR1 module scores [hazard ratio (HR) 2.2; 95% confidence
interval (CI) 1.1–4.1 and 2.2; 95% CI 1.2–4.2, respectively], see
Table 2 (significant risk estimates in bold) and supplementary
Figures S1 and S2, available at Annals of Oncology online.
Table 1. Patient and tumor characteristics of the patients included
in the translational TEX trial
Patients
Number Percent
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gene module scores representative of the
AKT-MTOR, RAS, and BETA-C signaling pathways
are associated with poor post-relapse survival
To further characterize the biology of our metastatic samples,
we extended our gene module analysis to include a set of 10 pre-
viously described biologically relevant signaling pathways (Ras,
MAPK, PTEN, AKT-MTOR, PI3KCA, IGF1, Src, Myc, E2F3,
and β-catenin) [14]. In summary, high AKT-MTOR (P log rank =
0.03, HR 1.7; 95% CI 1.1–2.7), RAS (P log rank = 0.03, HR 1.8,
95% CI 1.1–2.9), and BETA-C (P log rank = 0.03, HR 1.7, 95% CI
1.1–2.7) module scores were significantly associated with long-
term poor post-relapse survival (supplementary Figures S3–S6,
available at Annals of Oncology online).
breast cancer molecular subtypes of metastases
provide information of post-relapse survival
Overall, 25% of the metastases were basal-like (n = 30), 32%

















































































































































































































































































Figure 1. Hierarchical clustering of gene expression profiles of breast cancer metastases based on module genes reflecting seven biological processes (A)
Positively correlated module genes were selected for visual representation of 120 breast cancer metastatic samples. Arrows indicate patients with multiple
metastases. AURKA, proliferation; CASP3, apoptosis; ERBB2, HER2 signaling; ESR1, estrogen signaling; PLAU, tumor invasion/metastasis; STAT1, immune
response; VEGF, angiogenesis. (B) Zoom-in of CASP3 and VEGF modules.
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B (n = 34), and 5% normal-like. These subtypes were signifi-
cantly associated with survival in the Kaplan–Meier analysis
(P = 0.008, Figure 3A) with the shortest survival seen in the
basal-like and HER2-enriched subgroups. Furthermore, using a
multivariate proportional hazard (Cox) model adjusting for age
at diagnosis, diagnosis date, and TEX clinical study treatment
received, a more than threefold increased risk for death from
breast cancer was found in patients whose tumors were basal-
like and HER2-enriched (HR 3.7; 95% CI 1.3–10.9 and 4.4; 95%
CI 1.5–12.8, respectively), see Table 2.
basal-like, cell cycle, and mesenchymal-related
genes are upregulated in patients with short-term
post-relapse survival
Finally, in an effort to understand genetic differences between
tumors of patients with short-term versus long-term survival,
we carried out differential gene expression analysis to identify a
poor metastasis survival signature. The poor metastasis survival
signature included 136 unique genes differentially expressed
between patients with short-term compared with long-term
post-relapse survival. The expression of the included genes is
presented in supplementary Figure S7, available at Annals of
Oncology online and the full gene list is also provided in supple-
mentary Table S1, available at Annals of Oncology online.
Strikingly, patients with short-term survival (supplementary
Figure S7, available at Annals of Oncology online, red in the
horizontal sidebar) displayed increased expression of the epithe-
lial to mesenchymal marker SNAI1, the cell cycle markers
CCNE1, CDC25B, and the basal/triple-negative-associated gene
CAV2. Moreover, the same patients showed reduced expression
of the ESR1, GATA3, and FOXA1 genes, all of which are linked
to a luminal breast phenotype and ER receptor expression. A
gene ontology analysis of these 136 genes is also provided in
supplementary Table S2, available at Annals of Oncology online.
These results are in line with our earlier findings, showing a
worse survival outcome in patients with a low ESR1 module
score and basal-like subtype.
discussion
It is now accepted that standard breast cancer markers alter
their expression throughout tumor progression [2–5], which sig-
nificantly influences patient survival [2, 5]. As such, investiga-
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Figure 2. Long- and short-term breast cancer-specific post-relapse survival in relation to gene module groups (A) ESR1 module tertiles long-term (5 years)
and short-term (1.5 years) breast cancer-specific survival, respectively. (B) CASP3 module tertiles long- and short-term post-relapse survival, respectively. A
P value is based on the log-ranked test, and numbers at risk are shown underneath each graph.
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improve patient management and survival. However, in order to
be able to further individualize patient management in the
metastatic setting, we need a better understanding of the associ-
ation between metastatic tumor characteristics and patient sur-
vival. If tumor aggressiveness as assessed by the prognostic
markers in the primary setting can be translated to the metastat-
ic setting, this information would be clinically relevant.
To enhance our current understanding of tumor biology in
breast cancer metastases, we analyzed the TEX randomized trial
that included 111 patients with available gene expression infor-
mation from one or more metastatic lesions. Specifically, we
assessed gene modules representative of tumor biological pro-
cesses and pathways, as well as, the intrinsic subtypes [12], in all
metastatic samples and related our findings to patient survival.
Interestingly, a significant reduction in post-relapse breast
cancer-specific survival was demonstrated for patients with the
lowest levels of ER receptor signaling (ESR1 module) and apop-
tosis (CASP3). Furthermore, high AKT-MTOR, RAS, as well as
BETA-C (β-catenin) signaling were significantly associated with
poor post-relapse survival. Similarly, the intrinsic subtypes in
the metastases provided statistically significant post-relapse sur-
vival information, with the worst survival outcome in the basal-
like and HER2-enriched subtypes. Additionally, patients with
poor post-relapse survival showed high metastasis expression
levels of basal-like, cell cycle, and mesenchymal-related genes
with concomitant low expression of luminal genes.
While little is known about the biology of breast cancer me-
tastases themselves, the steps governing the progression from
primary breast tumor to seeding of distant metastatic lesions
has been a focal point of intense investigation (for review see
refs. [16, 17]). These steps comprise what is typically termed ‘the
metastatic cascade’ and consist of invasion/proliferation into the
tissue surrounding the primary tumor, intravasation to blood or
lymph vessels, extravasation to distal organs, and finally colon-
ization of the distant tumor microenvironment. With regard to
colonization, one of the main processes that have been hypothe-
sized as essential to the successful development of metastatic
breast tumors is cell proliferation [17]. Through application of
the AURKA gene module, we demonstrate that the vast majority
of our samples are highly proliferative; this finding is also sup-
ported by the intrinsic subtypes where the majority of tumors are
luminal B, HER2-enriched, and basal-like subtypes—all of which
are associated with high levels of proliferation. Of note, the
luminal A subtype of tumors that are known to display lower
levels of proliferation have the best post-relapse survival in our
dataset [18]. These results may emphasize the importance of pro-
liferation in relation to survival in metastatic tumors, at least in
tumors of luminal subtype, and indicate that a routinely
employed proliferative marker, such as Ki-67, could also prove
informative in a clinical setting.
In conclusion, an enhanced understanding of the biology of
breast cancer metastases is needed to improve both patient sur-
vival in the metastatic setting and prediction of which patients
are at high risk to later develop metastatic breast cancer disease.
We show that the tumor characteristics of metastases signifi-
cantly influence post-relapse patient survival emphasizing that
molecular investigation at relapse offers clinically relevant infor-
mation, with the potential to improve patient management and
survival in the relapse setting.
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Table 2. Multivariate analysis of gene modules and subtypes in relation to patient post-relapse survival
Long-term breast cancer-specific survival Short-term breast cancer-specific survival
b
HR 95% CI P value HR 95% CI P value
Modulea (n = 111)
ESR1 lowc 1.3 0.8–2.1 0.27 2.2 1.2–4.2 0.01
ERBB2 high
d
0.8 0.5–1.4 0.46 0.8 0.4–1.5 0.47
AURKA high
d
1.2 0.8–2.0 0.38 1.1 0.5–2.1 0.89
PLAU high
d
1.2 0.7–1.9 0.52 1.4 0.8–2.7 0.25
VEGF lowc 1.0 0.6–1.6 0.95 1.5 0.8–2.8 0.21
STAT1 lowc 1.0 0.6–1.6 0.99 0.8 0.4–1.6 0.58
CASP3 lowc 2.7 1.7–4.5 <0.001 2.2 1.1–4.1 0.02
PAM50a (n = 105)
Luminal A (Ref.) 1.0 – – 1.0 – –
Luminal B 2.3 0.8–6.9 0.12 2.4 0.3–19.5 0.42
HER2-enriched 4.4 1.5–12.8 0.01 7.6 1.0–58.2 0.05
Basal-like 3.7 1.3–10.9 0.02 7.2 1.0–54.6 0.06
aAdjusted for age at diagnosis, diagnosis date, and treatment received.
b1.5-year survival.
cIntermediate/high as reference group.
dLow/intermediate as reference group.
HR, hazard ratio; CI, confidence interval.
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Figure 3. The PAM50 intrinsic subtypes in relation to long- and short-term post-relapse breast cancer-specific survival. (A) The PAM50 intrinsic subtypes in
relation to long-term (5 years) breast cancer-specific survival. (B) The PAM50 intrinsic subtypes in relation to short-term (1.5 years) breast cancer-specific
survival. A P value is based on log-ranked test, and numbers at risk are shown underneath each graph.
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